- Home
- ENGN vs TECX Comparison
ENGN vs TECX Comparison
Compare ENGN & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- TECX
- Stock Information
- Founded
- ENGN 1999
- TECX 2019
- Country
- ENGN Canada
- TECX United States
- Employees
- ENGN N/A
- TECX N/A
- Industry
- ENGN
- TECX
- Sector
- ENGN
- TECX
- Exchange
- ENGN Nasdaq
- TECX Nasdaq
- Market Cap
- ENGN 204.3M
- TECX 334.4M
- IPO Year
- ENGN N/A
- TECX 2018
- Fundamental
- Price
- ENGN $3.63
- TECX $19.91
- Analyst Decision
- ENGN Buy
- TECX Buy
- Analyst Count
- ENGN 7
- TECX 6
- Target Price
- ENGN $23.29
- TECX $78.67
- AVG Volume (30 Days)
- ENGN 91.9K
- TECX 244.3K
- Earning Date
- ENGN 06-12-2025
- TECX 08-13-2025
- Dividend Yield
- ENGN N/A
- TECX N/A
- EPS Growth
- ENGN N/A
- TECX N/A
- EPS
- ENGN N/A
- TECX N/A
- Revenue
- ENGN N/A
- TECX N/A
- Revenue This Year
- ENGN N/A
- TECX N/A
- Revenue Next Year
- ENGN N/A
- TECX N/A
- P/E Ratio
- ENGN N/A
- TECX N/A
- Revenue Growth
- ENGN N/A
- TECX N/A
- 52 Week Low
- ENGN $2.65
- TECX $13.70
- 52 Week High
- ENGN $11.00
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- ENGN 52.57
- TECX 43.97
- Support Level
- ENGN $2.95
- TECX $17.97
- Resistance Level
- ENGN $3.44
- TECX $20.75
- Average True Range (ATR)
- ENGN 0.37
- TECX 1.40
- MACD
- ENGN 0.01
- TECX -0.36
- Stochastic Oscillator
- ENGN 59.48
- TECX 26.93
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.